Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients
Purpose: To evaluate long-term antimuscarinic drug persistence and its associated characteristics in patients with overactive bladder (OAB) treated with antimuscarinic agents. We also assessed the efficacy and safety of switching from solifenacin to mirabegron in patients refractory to antimuscarini...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-01-01
|
Series: | Journal of the Formosan Medical Association |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664617306514 |
id |
doaj-134ca89f47aa4a9f8e57d6cf1a8a1218 |
---|---|
record_format |
Article |
spelling |
doaj-134ca89f47aa4a9f8e57d6cf1a8a12182020-11-25T02:49:35ZengElsevierJournal of the Formosan Medical Association0929-66462019-01-011181279284Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patientsChung-Cheng Wang0Hann-Chorng Kuo1Department of Urology, En Chu Kong Hospital, College of Medicine, National Taiwan University, New Taipei, Taiwan; Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan, TaiwanDepartment of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan; Corresponding author. Department of Urology, Buddhist Tzu Chi General Hospital, 707, Section 3, Chung-Yang Road, Hualien, Taiwan. Fax: +886 3 8560794.Purpose: To evaluate long-term antimuscarinic drug persistence and its associated characteristics in patients with overactive bladder (OAB) treated with antimuscarinic agents. We also assessed the efficacy and safety of switching from solifenacin to mirabegron in patients refractory to antimuscarinic therapy. Methods: In this prospective, open-label, 48-month study, 416 patients (mean age, 70.6 ± 12.4 years) were enrolled. All patients completed the overactive bladder symptom score and urgency severity score questionnaires, along with initial and follow-up uroflowmetry. All patients received antimuscarinic solifenacin 5 mg daily. Mirabegron (25 mg daily) was suggested in patients that were refractory to antimuscarinic therapy or had intolerable side effects. Results: The mean solifenacin persistence was 6.6 ± 8.1 months (range, 0.5–48 months). Only 81 (19.5%) patients had drug persistence of ≥12 months. Male sex, age, cerebral vascular accident, maximum flow rate, and post-void residual were associated with solifenacin persistence in the univariate analysis. Age (odds ratio [OR], 0.14; 95% CI, 0.08–0.21) was the only independent predictor in the multivariate logistic regression. Of the 416 patients, 171 (60.8%) changed from solifenacin to mirabegron for due to the persistence of OAB symptoms. The switch resulted in a significantly longer period of actual OAB pharmacotherapy (9.3 ± 9.2 vs 13.3 ± 9.3 months, p < 0.001). Conclusion: Long-term drug persistence of solifenacin was low during the 2-year follow-up. Age was an independent factor associated with longer drug persistence. Switching from solifenacin to mirabegron was an effective and safe alternative for OAB patients that were refractory to solifenacin treatment. Keywords: Drug persistence, Mirabegron, Muscarinic antagonist, Overactive bladder, Solifenacinhttp://www.sciencedirect.com/science/article/pii/S0929664617306514 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chung-Cheng Wang Hann-Chorng Kuo |
spellingShingle |
Chung-Cheng Wang Hann-Chorng Kuo Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients Journal of the Formosan Medical Association |
author_facet |
Chung-Cheng Wang Hann-Chorng Kuo |
author_sort |
Chung-Cheng Wang |
title |
Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients |
title_short |
Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients |
title_full |
Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients |
title_fullStr |
Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients |
title_full_unstemmed |
Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients |
title_sort |
factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients |
publisher |
Elsevier |
series |
Journal of the Formosan Medical Association |
issn |
0929-6646 |
publishDate |
2019-01-01 |
description |
Purpose: To evaluate long-term antimuscarinic drug persistence and its associated characteristics in patients with overactive bladder (OAB) treated with antimuscarinic agents. We also assessed the efficacy and safety of switching from solifenacin to mirabegron in patients refractory to antimuscarinic therapy. Methods: In this prospective, open-label, 48-month study, 416 patients (mean age, 70.6 ± 12.4 years) were enrolled. All patients completed the overactive bladder symptom score and urgency severity score questionnaires, along with initial and follow-up uroflowmetry. All patients received antimuscarinic solifenacin 5 mg daily. Mirabegron (25 mg daily) was suggested in patients that were refractory to antimuscarinic therapy or had intolerable side effects. Results: The mean solifenacin persistence was 6.6 ± 8.1 months (range, 0.5–48 months). Only 81 (19.5%) patients had drug persistence of ≥12 months. Male sex, age, cerebral vascular accident, maximum flow rate, and post-void residual were associated with solifenacin persistence in the univariate analysis. Age (odds ratio [OR], 0.14; 95% CI, 0.08–0.21) was the only independent predictor in the multivariate logistic regression. Of the 416 patients, 171 (60.8%) changed from solifenacin to mirabegron for due to the persistence of OAB symptoms. The switch resulted in a significantly longer period of actual OAB pharmacotherapy (9.3 ± 9.2 vs 13.3 ± 9.3 months, p < 0.001). Conclusion: Long-term drug persistence of solifenacin was low during the 2-year follow-up. Age was an independent factor associated with longer drug persistence. Switching from solifenacin to mirabegron was an effective and safe alternative for OAB patients that were refractory to solifenacin treatment. Keywords: Drug persistence, Mirabegron, Muscarinic antagonist, Overactive bladder, Solifenacin |
url |
http://www.sciencedirect.com/science/article/pii/S0929664617306514 |
work_keys_str_mv |
AT chungchengwang factorsassociatedwithantimuscarinicdrugpersistenceandincreasingdrugpersistenceafterswitchingtomirabegronforoveractivebladderpatients AT hannchorngkuo factorsassociatedwithantimuscarinicdrugpersistenceandincreasingdrugpersistenceafterswitchingtomirabegronforoveractivebladderpatients |
_version_ |
1724742632143323136 |